SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs > CYTODYN INC (CYDY)

We have a management team that should have

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
pearsby09 Member Profile
 
Followed By 8
Posts 1,665
Boards Moderated 1
Alias Born 04/29/16
160x600 placeholder
Small Company Offering and Sale of Securities Without Registration (d) "Edgar (US Regulatory)" - 11/16/2017 4:12:12 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/8/2017 4:34:16 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/8/2017 4:34:01 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/2/2017 4:33:11 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/13/2017 7:20:39 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 10/11/2017 7:53:23 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/11/2017 7:46:31 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 10/10/2017 9:05:18 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/5/2017 2:56:11 PM
Proxy Statement (definitive) (def 14a) "Edgar (US Regulatory)" - 10/2/2017 10:00:24 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) "Edgar (US Regulatory)" - 9/20/2017 5:10:21 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 9/8/2017 7:49:58 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/8/2017 7:45:54 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/6/2017 7:01:46 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/25/2017 7:32:05 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/21/2017 4:06:51 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/9/2017 4:05:34 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/31/2017 5:41:30 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/31/2017 5:04:43 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/28/2017 4:09:10 PM
Amended Annual Report (10-k/a) "Edgar (US Regulatory)" - 7/27/2017 5:24:15 PM
Proxy Statement (definitive) (def 14a) "Edgar (US Regulatory)" - 7/24/2017 7:42:19 AM
Annual Report (10-k) "Edgar (US Regulatory)" - 7/20/2017 6:05:42 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/14/2017 4:09:06 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) "Edgar (US Regulatory)" - 7/10/2017 5:29:50 PM
pearsby09   Thursday, 11/09/17 02:54:56 PM
Re: None
Post # of 18300 
We have a management team that should have set extremely conservative time lines due to past misses. Therefor to attempt a level of credibility they hopefully set a time frame of enrollment to be met or surpassed. The relaxed entry criteria should add to the expeditious enrollment process. PRO 140 has been advocated due to a some what pristine Efficacy/Safety profile..i.e. to avoid the so called toxic nature of the existing HAART alternatives. The back log of candidates that now can enter due to the new criteria should be a slam dunk, especially with all the delays. We are looking for 10 or so patients in an unmet disease state with complications set forth by existing therapies..ONLY 10! With all of the reasons above, DEC.1st should be the anticipated time line. Another miss will invalidate the HAART deficiency's. I hope we do not even MEET the time lines, let alone another delay per the above rationale for BEATING the time lines.

BEAT the Timelines...Huge credibility and pps move
MEET the timelines...Some what neutral
MISS the new timelines (even by a couple of weeks) Credibility gone (4 times over)...pps plummets and Big Pharma watching it waste away to prices that CYDY may have to conform and concede to, especially with only ONE Suitor.
Keep in mind, Obviously, a BO is all they have.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist